Cardiovascular Warning Boosts Profile For OTC NSAID Label Changes
This article was originally published in The Tan Sheet
Executive Summary
FDA more commonly requires similar changes for prescription drug labels based on emerging science on potential risks, but for non-aspirin NSAID label changes CDER also will contact OTC firms and advise them of changes needed to cardiovascular risk warnings on their product labels. “It doesn’t happen on quite the scale that we’re dealing with here and with the nature of these products,” says attorney Frederick Stearns.
You may also be interested in...
Joint Supplement Safer Than NSAID Diclofenac For Osteoarthritis Pain – Study
Wobenzym, an oral enzyme combination supplement could serve as an alternative to Rx NSAID diclofenac, as it is as effective but associated with less treatment-emergent adverse events, finds a Journal of Pain Research study.
Jurors' Answers In FTC Complaint Against Prevagen Might Form A Memory Bubble For Health Claims
“No” answers in New York federal court on whether all but two of Prevagen claims were “materially misleading” could put a fork in the road of a long dispute between FTC and supplement product manufacturers and marketers.
MLM Group Not Buying FTC Executive’s Concerns About Its Income Disclosure Guidance
FTC Division of Marketing Practices assistant director concerned direct selling self-regulation group’s guidance “will encourage deceptive conduct and facilitate deceptive earnings claims.” DSA president says the concerns might reflect the thinking of agency’s staff more than the intent of the agency’s regulations.